- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Bradley Prechtl on How Community Oncologists Can Work With Employers
Bradley Prechtl, MBA, chief executive officer of Florida Cancer Specialists and the American Oncology Network discusses how Florida Cancer Specialists is working with employers.
Bradley Prechtl, MBA, chief executive officer of Florida Cancer Specialists and the American Oncology Network discusses how Florida Cancer Specialists is working with employers.
Transcript
With employers playing a more active role in the health of their employees, how is Florida Cancer Specialists working with employers?
We’re partnering with employers. I think the goal is to really, in many parts of the country and Florida is not different, we’re trying to go directly to the employers and have partnerships and work and have open lines of communication about what’s happening within the cancer community and equally important what’s happening within their base of employees and covered dependents.
Cancer’s typically going to be one of the top 2 or 3 highest expenses that an employer will incur related to the care of their employee base and their covered dependents. So, we’ve been, for the last couple of years, partnering with these large employers trying to number 1 make sure there’s good access to care, number 2 improving quality, and equally important, lowering expenses.
Alopecia Areata Treatment Advancements and Emerging Technology
November 4th 2024Kristen Whitney, DO, FAAD, dermatologist at Allegheny Health Network, highlighted recent breakthroughs in treating alopecia areata, focusing on the effectiveness of Janus kinase inhibitors and the ongoing challenges related to insurance coverage and patient access.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
